Item 5. Market for Registrant’s Common Equity
Item
5.
Market
for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
(a)
Market
Information
Our
common stock is quoted on the OTCQB under the symbol “RAKR”. The high and low bid prices of our common stock for the periods
indicated below are as follows:
OTCQB
Quarter Ended
High*
Low*
December 31, 2021
$ 0.0483
$ 0.0149
September 30, 2021
$ 0.07
$ 0.0323
June 30, 2021
$ 0.089
$ 0.0331
March 31, 2021
$ 0.128
$ 0.0551
December 31, 2020
$ 0.135
$ 0.071
September 30, 2020
$ 0.7411
$ 0.1202
June 30, 2020
$ 0.20
$ 0.125
March 31, 2020
$ 0.4851
$ 0.091
*Source: yahoo!finance Historical Data
Quotations
reflect inter dealer prices, without retail mark up, markdown or commissions and may not represent actual transactions.
(b)
Holders
The
number of holders of record of RAKR common stock at the time of filing was approximately 4,326. Many of our shares of common stock are
held by brokers and other institutions on behalf of stockholders, so we are unable to estimate the number stockholders represented by
the record holders.
The
transfer agent for RAKR common stock is Pacific Stock Transfer, 6725 Via Austi Pkwy, Suite 300 Las Vegas, NV 89119.
12
(c)
Dividends
The
Company has not paid any cash dividends to date and does not anticipate or contemplate paying dividends in the foreseeable future. It
is the present intention of management to utilize all available funds for the development of the business.
(d)
Securities
Authorized for Issuance Under Equity Compensation Plans
Commencing
July 3, 2017 through year ending 2020, in fulfillment of conditions contained in the 2017 share exchange agreement and other contracts,
the Board authorized a number of options to executives, consultants and other third parties that have since been cancelled.
On
January 22, 2020, the Company entered into a three-year consulting agreement with a third party for consulting and business development
services. The contract included warrants of which 25,000,000 remain in effect exercisable at $0.20 and expire January 21, 2023.
On
January 21, 2020, the Company entered into a three-year consulting agreement with a company controlled by its new CEO. The contract included
3,600,000 warrants with an exercise price of $0.20 vesting in equal amounts commencing the effective date of the contract. On December
31, 2020, this contract was terminated. The warrants vested immediately, and the exercise price was amended to $0.10. As well, the Company
granted an additional 500,000 warrants which vested immediately at an exercise price is $0.10. All expire December 31, 2025.
On
October 1, 2020, the Company entered into a consulting agreement with an Advisor which granted warrants in full compensation for services.
It included 13,500,000 warrants at an exercise price of $0.30 expiring October 1, 2023 and of 15,000,000 warrants at an exercise price
of $0.15 expiring October 1, 2025.
On
April 1, 2021, the Company granted 4,100,000 options as part of an amendment to an Executive Consultant’s contract; 125,000 options
vest per month commencing April 1, 2021 with a term of 5 years and exercisable at a price of $0.10 per Share.
On
December 21, 2021, the Company granted 500,000 options to each of the two new Directors; for each, 100,000 options vested immediately
and the balance vests over the remaining term of their appointment; each with a term of 5 years and exercisable at $0.10 per share or
with a 20% discount to market based on a 30-day VWAP if it falls below $0.10, not to go below $0.07.
Item
6.
Selected
Financial Data
Not
applicable.